John J Daly

US Patent:

48836613, Nov 28, 1989

Filed:

Oct 9, 1987

Appl. No.:

7/107287

Inventors:

John M. Daly - Haverford PA
John Reynolds - Philadelphia PA

International Classification:

A61K 3702
A61K 4502

US Classification:

424 852

Abstract:

It has been found that arginine serves to increase the receptivity of cells to lymphokines such as interleukin-2 and interferon. An improved method for treating a mammal with one or more lymphokines is disclosed wherein said improvement comprises administering said one or more lymphokines to said mammal in combination with an amount of arginine effective to increase the receptivity of cells of said mammal to said one or more lymphokines.

US Patent:

45955220, Jun 17, 1986

Filed:

Dec 12, 1983

Appl. No.:

6/560727

Inventors:

Philip L. Bartlett - Wilmington DE
John J. Daly - Wilmington DE
John D. Sterling - Wilmington DE

Assignee:

E. I. Du Pont de Nemours and Company - Wilmington DE

International Classification:

C09K 330
C11D 1700
A61L 904
A61K 700

US Classification:

252305

Abstract:

Propellant gas compositions for aerosol products are disclosed consisting essentially of monochlorodifluoromethane, dimethyl ether and a hydrocarbon selected from the group consisting of butane, isobutane and mixtures thereof, said compositions having a vapor pressure of about 50 to 60 psig at 70. degree. F.

US Patent:

45855773, Apr 29, 1986

Filed:

Dec 12, 1983

Appl. No.:

6/560728

Inventors:

Philip L. Bartlett - Wilmington DE
John J. Daly - Wilmington DE
John D. Sterling - Wilmington DE

Assignee:

E. I. Du Pont de Nemours and Company - Wilmington DE

International Classification:

C09K 330
C11D 1700
A61L 904

US Classification:

252305

Abstract:

Propellant gas compositions for aerosol products are disclosed consisting essentially of monochlorodifluoromethane, dimethyl ether and methylene chloride, said compositions having a vapor pressure of about 50 to 60 psig at 70. degree. F.

US Patent:

45432023, Sep 24, 1985

Filed:

Mar 23, 1984

Appl. No.:

6/592881

Inventors:

Philip L. Bartlett - Wilmington DE
John J. Daly - Wilmington DE
John D. Sterling - Wilmington DE

Assignee:

E. I. Du Pont de Nemours and Company - Wilmington DE

International Classification:

C09K 330

US Classification:

252305

Abstract:

Propellant gas compositions for aerosol products consisting essentially of monochlorodifluoromethane, dimethyl ether and 1-chloro-1,1-difluoroethane, said compositions having a vapor pressure of about 50 to 60 psig at 70. degree. F.

US Patent:

20160283921, Sep 29, 2016

Filed:

Mar 26, 2015

Appl. No.:

14/669165

Inventors:

- Danbury CT, US
Lingyun Su - Philadelphia PA, US
John Daly - Mendham NJ, US

International Classification:

G06Q 20/10
G06Q 50/22
G06F 19/00

Abstract:

A computer-implemented method includes receiving a treatment record descriptive of a pharmacy purchase transaction that includes a prescriber identification code and a pharmaceutical compound related to treatment for an individual disease state, and associating the received treatment record with a code indicative of a provider network. The treatment record is related to a time-based treatment record descriptive of a projected disease state for a specified treatment area and a treatment model is developed based on relating the received treatment record to the time-based treatment record. The treatment model indicates projected occurrences of the disease state over a specified time frame, the projected occurrences including a first code indicative of a prescribing authority, the treatment model also including an association label that identifies a linkage between treatment records with a threshold degree of similarity. Referencing a provider network behavioral model for the provider network based on the code indicative of the provider network, and using the code indicative of the provider network to update the provider network behavioral model. Comparing the updated provider network behavioral model to the treatment model, and generating an instruction record for the specified treatment area, wherein generating the instruction record comprises generating an aggregated impact label indicative of addressable disease states for a specified treatment area.